MRIdian Radiation Therapy for Pancreatic Cancer
Key Clinical Study
A retrospective study at five MRIdian centers showed that high-dose adaptive treatment improves overall survival and eliminates serious toxicity in patients with pancreatic cancer.
Ongoing Clinical Study
Stereotactic MRI-Guided On-Table Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer
High-dose magnetic resonance imaging (MRI) guided hypofractionated radiation therapy delivered using daily adaptive dose planning has been shown in a retrospective study to result in improved overall survival, relative to patients receiving lower radiation doses, in patients with locally advanced pancreatic cancer, without increasing the rate of serious gastrointestinal toxicity.
The goal of the proposed trial is to investigative in a controlled, prospective manner the robustness of this outcome, and to track quality of life over a 5-year trial period.
Eligible Participants
Patients with borderline resectable or inoperable locally advanced pancreatic cancer who are 18 years and older and meet the inclusion and exclusion criteria noted within the study description.
Trial Design
In this single-arm study, participants will receive radiation therapy using integrated magnetic resonance imaging (ViewRay’s MRIdian MR-Guided Radiation Therapy System) at a dose of 50 Gray in 5 fractions (treatment sessions). Fractions will be delivered at least twice per week and with at least 18 hours between treatments. Each participant will be aligned in the treatment system with MRI-guidance. On-table adaptive replanning will be used when clinically indicated. In all patients, real-time MR-imaging will be used throughout treatment delivery to monitor the target location and control the radiation beam, as necessary.
Outcome Measures
The primary outcome measure of the study is grade 3 or higher gastrointestinal toxicity in the first 90 days after treatment. Secondary measures include overall survival at two years, distant progression-free survival at six months, and changes in patient-reported quality of life (pre-treatment to 12 months post-treatment and for longer periods up to five years).
Videos Related To Pancreatic Cancer
Patient Story: Michael Vaquero, Pancreatic Cancer
August 13, 2020
ViewRay MRIdian for Prostate, Breast, and Pancreatic Cancer Treatment
October 22, 2019
MRI-Guided Radiation Therapy Panel
Radiation oncology experts from across the country gathered to discuss the potential of MRI-guided radiotherapy.
Miami Cancer Institute, Baptist Health South Florida
September 28, 2018
October 8, 2018
Scientific Presentations Related To Pancreatic Cancer
MR-Guided SBRT for Pancreas with On-Table Adaptation on MRIdian – MCI Experience
Michael Chuong, MD
Miami Cancer Institute, Baptist Health South Florida
ASTRO 2019
Dr. Chuong has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.
SMART: Status Update on the First Prospective, Multi-Institutional Study on Ablative Pancreas SBRT
Parag Parikh, MD
Henry Ford Health System
ASTRO 2019
Dr. Parikh has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.
Quantitative Radiomics of Daily 0.35T MR Images for Prediction of Tumor Response in Pancreas and Liver
John Chetley Ford, PhD
Sylvester Comprehensive Cancer Center, University of Miami Health System
ASTRO 2018
Dr. Ford has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.
High Dose, On-Table, Adaptive Radiation Therapy for Pancreatic Cancer: Encouraging Early Results
Michael Bassetti, M.D., Ph.D. | Assistant Professor, Radiation Oncology
University of Wisconsin, Carbone Cancer Center
Miami Symposium (2018)
Dr. Bassetti has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.
Improving Pancreatic Cancer Survival by using MR Guided Adaptive Radiation
Parag Parikh, BSE, MD
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine – St. Louis, MO
ASTRO 2017
Dr. Parikh has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.
From Anatomical to Functional-based MR Guided Adaptive Radiotherapy: The UCLA Experience
Percy Lee, MD
UCLA Health, Jonsson Comprehensive Cancer Center – Los Angeles, CA
ASTRO 2017
Dr. Lee has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.
Clinical Experience with MR-guided Radiation Therapy for Pancreatic Tumors at VUmc
Anna Bruynzeel, MD, PhD
VUmc – Amsterdam, The Netherlands
ASTRO 2017
Dr. Bruynzeel has been compensated by ViewRay for her services in preparing and presenting this material for ViewRay’s further use and distribution.
Daily Adaptive Planning for Pancreatic Cancer
Frank Lagerwaard, MD
VUmc – Amsterdam, The Netherlands
ASTRO 2017
Dr. Lagerwaard has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.
Considerations and Challenges of MR Guided RT
John Bayouth, PhD
Carbone Cancer Center, University of Wisconsin – Madison, WI
ESTRO 37 (2018)
Dr. Bayouth has been compensated by ViewRay for his services in preparing and presenting this material for ViewRay’s further use and distribution.